

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification⁶: C07D 239/56, A61K 31/505	A1	(11) International publication number: WO 99/09015 (43) International publication date: 25 February 1999 (25.02.99)
(21) International application number: PCT/EP98/05178 (22) International filing date: 14 August 1998 (14.08.98) (30) Data relating to the priority: 197 35 410.6 14 August 1997 (14.08.97) DE (71) Applicant (for all designated States except US): BASF AKTIENGESELLSCHAFT [DE/DE]; D-67056 Ludwigshafen (DE). (72) Inventors; and (75) Inventors/Applicants (US only): BLANK, Stefan [DE/DE]; Drachenfelsstrasse 47, D-67056 Ludwigshafen (DE). STARCK, Dorothea [DE/DE]; Kaiser-Wilhelm-Strasse 31, D-67059 Ludwigshafen (DE). TREIBER, Hans-Jörg [DE/DE]; Sperberweg 1, D-68782 Brühl (DE). KOSER, Stefan [DE/DE]; Brahmstrasse 9, D-67061 Ludwigshafen (DE). SCHÄFER, Bernd [DE/DE]; Hauptstrasse 22, D-76889 Dierbach (DE). THYES, Marco [LU/DE]; Mendelssohnstrasse 31, D-67061 Ludwigshafen (DE). HÖGER, Thomas [DE/DE]; Rathenaustrasse 12, D-68535 Edingen-Neckarhausen (DE). (74) Attorney: REITSTÖTTER, KINZEBACH & PARTNER; Sternwartstrasse 4, D-81679 Munich (DE).		(81) Designated states: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With the International Search Report.</i>
As printed (54) Title: 2-{3-[4-(2-T-BUTYL-6- TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARATE (54) Bezeichnung: 2-{3-[4-(2-T-BUTYL-6- TRIFLUORMETHYLPYRIMIDIN-4-YL) PIPERRAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARAT (57) Abstract The invention relates to the fumaric acid salt from 2-{3-[4-(2-t-butyl)-6- trifluoromethylpyridin-4-yl] piperazin-1-yl} propylmercapto} pyrimidin-4-ol and to pharmaceutical agents containing said salt. The salt can be used for treating diseases which respond to dopamine-D ₃ ligands. It is very stable at a low pH and is therefore especially suitable for oral administration. (57) Zusammenfassung Die vorliegende Erfindung betrifft das Fumarsäuresalz von 2-{3-[4-(2-t-Butyl)-6- trifluormethylpyrimidin-4-yl] piperazin-1-yl} propylmercapto} pyrimidin-4-ol sowie pharmazeutische Mittel, welche dieses Salz enthalten. Das Salz ist zur Behandlung von Erkrankungen, die auf Dopamin-D ₃ -Liganden ansprechen, brauchbar. Es besitzt erhöhte Stabilität bei niedrigem pH und ist daher zur oralen Applikation besonders geeignet.		